Publication regulations and reporting requirements
DZIF Transplant Cohort e.V.

In principle, the identification of the persons to be listed and the order in which they are listed must be in accordance with the guidelines of the respective study teams and the rules of good scientific practice of the DFG.

Authorized authors are:

- The study management, according to the management of the specific study, which draws on the resources of the transplant cohort
- Persons significantly involved in the implementation of the study, e.g. research assistants, biometricians, epidemiologists, computer scientists, etc.
    - This applies in particular to persons who have supported applicants with regard to evaluation, analysis and data quality under the connection to the TI BBD
- 1 clinical representative per organ group of the data- and/or sample-providing centers involved in the study, provided that data and/or samples from at least 5 patients were used.
- Alternatively, persons who are not assigned to a direct organ group but belong to associated disciplines such as virology, microbiology, immunology, etc. can also be named.
- The decision as to which person should be named for a publication is made by the respective cohort board representative of a site in consultation with the local clinical coordination. The sites are requested to keep an internal list for this purpose.
- The centers should name the person who has actively provided the relevant amount of data and/or samples for the cohort for the present research question or who has actively worked to obtain the necessary resources by other means, including in the past.
- The participating centers and their representatives to be named will be communicated to the study management by the management
- If data and/or samples from several departments of a center have been used for a study, representatives of all these departments must be named.
- If no co-authorship is desired by the centers supplying data and/or samples, the study management must obtain written confirmation of this.
- If data and/or samples from fewer than 5 patients were used, representatives of the respective centers may be named as authors in exceptional cases, provided that these resources contributed significantly and primarily to the conduct of the study.

Order of the listed authors:

- The order of authors is determined by the study management in consultation with the entire study team or a person from the study team designated by the study management.
- Co-authorships are due to the other significantly involved employees in an order to be determined internally, as well as representatives of the departments supplying data and/or samples, in the order of the amount of material supplied.
- If the number of authors is limited by the respective journal, the study management must reach a consensus with the study team and the representatives of the institutions supplying the data and/or samples.
- The addition “and members of the German Centre of Infection Research Transplant Cohort” should appear in the list of authors after the authors listed by name. Members in this sense are all physicians and scientists involved in the collection and management of patient data and patient samples at the various centers. The list of these names should appear in a footnote or similar in the manuscript to be published.

Agreements and documentation requirements

- The study management is responsible for consultation with all persons and institutions involved.
- Before each publication, the study management must obtain written confirmation from the centers providing data and/or samples whose representatives are to be named in the corresponding publication.
- The publication draft must be submitted to all listed authors prior to submission.
- The consent of the listed authors must be documented.
- The study management must obtain written confirmation from the data- and/or sample-providing centers if no named co-authorship is desired.

Disclosure of conflicts of interest

- Financial or other potential conflicts of interest must be disclosed (e.g. listing of memberships in advisory boards, other advisory functions, receipt of fees from the pharmaceutical industry, shareholdings, research funds, etc.).

Publication obligation

- The results of each study and the data obtained from the biosamples must be made available to the cohort for unrestricted, non-commercial publication. For further details, please also refer to the preliminary application form. Each member is responsible for obtaining the necessary consent from any third parties involved in the study and must provide evidence of this to the management. The following formats are possible:
- Report for non-publishable results, which contains at least the objective of the study, the methodology, the resources used, the results and a brief discussion
- Published studies are presented - depending on the conditions of the journal - as a PDF or as a link on the transplant cohort website.
- The report must be submitted within one year of the end of the project period.

Mandatory passage

1. passage in the acknowledgement: The following text module must be included in the acknowledgement of each publication: This study was conducted with resources provided by the DZIF transplant cohort e.V. (https://www.dzif.de/en/working-group/transplant-cohort), support code TTU 07.701.

2. if one of the authors belongs to a DZIF site, the publication guidelines of the DZIF e.V. must also be followed:

a. Mention the DZIF affiliation: “German Center for Infection Research (DZIF)”

b. In addition, the location can be listed, e.g. “German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig”